CALL/EVOTEC/40/0.1/20.12.24 Share Price

Warrant

DE000GP9V0Z2

Market Closed - BOERSE MUENCHEN 19:26:23 24/05/2024 BST
0.015 EUR -40.00% Intraday chart for CALL/EVOTEC/40/0.1/20.12.24
Current month-44.44%
1 month-57.14%
Date Price Change
24/05/24 0.015 -40.00%
23/05/24 0.025 -3.85%
22/05/24 0.026 -7.14%
21/05/24 0.028 -3.45%
20/05/24 0.029 +7.41%

Real-time BOERSE MUENCHEN

Last update May 24, 2024 at 07:26 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying EVOTEC SE
Issuer Goldman Sachs
WKN GP9V0Z
ISINDE000GP9V0Z2
Date issued 20/07/2023
Strike 40
Maturity 20/12/2024 (208 Days)
Parity 10 : 1
Emission price 0.09
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.152
Lowest since issue 0.014
Delta0.08x
Omega 3.584
Premium354.49x
Gearing44.23x
Moneyness 0.2211
Difference Strike 31.16
Difference Strike %+77.89%
Spread 0.01
Spread %40.00%
Theoretical value 0.0200
Implied Volatility 108.36 %
Total Loss Probability 98.68 %
Intrinsic value 0.000000
Present value 0.0200
Break even 40.20 €
Theta-0x
Vega0x
Rho0x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.845 EUR
Average target price
20.79 EUR
Spread / Average Target
+135.05%
Consensus